<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   The diffuse alveolar hemorrhage syndromes
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       The diffuse alveolar hemorrhage syndromes
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        The diffuse alveolar hemorrhage syndromes
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonye K Danoff, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Hallowell, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bleeding into the alveolar spaces of the lungs characterizes the syndrome of diffuse alveolar hemorrhage (DAH) and is due to disruption of the alveolar-capillary basement membrane. This disruption is caused by injury or inflammation of the arterioles, venules, or alveolar septal (alveolar wall or interstitial) capillaries. Hemoptysis is the usual presenting symptom; however, it is not always present, even when hemorrhage is severe [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         An overview of the DAH syndromes will be presented here. The evaluation and treatment of hemoptysis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4333.html" rel="external">
          "Evaluation of nonlife-threatening hemoptysis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15663.html" rel="external">
          "Etiology of hemoptysis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ETIOLOGY AND HISTOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of diseases are associated with the development of the diffuse alveolar hemorrhage (DAH) syndrome  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,3-21
         </a>
         ]. The underlying cause of DAH is generally reflected in the histopathologic pattern, which therefore has both therapeutic and prognostic implications. One of three different histopathologic patterns may be seen: pulmonary capillaritis, bland pulmonary hemorrhage, and diffuse alveolar damage (DAD).
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Pulmonary capillaritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathologic pattern of pulmonary capillaritis, also referred to as alveolar capillaritis, is characterized by neutrophilic infiltration of the alveolar septa (lung interstitium)  (
         <a class="graphic graphic_picture graphicRef76904 graphicRef56943" href="/z/d/graphic/76904.html" rel="external">
          picture 1A-B
         </a>
         ), which sequentially leads to necrosis of these structures, loss of capillary structural integrity, and spilling of red blood cells into the alveolar space and interstitium [
         <a href="#rid3">
          3-6,22-25
         </a>
         ].
        </p>
        <p>
         Many of the neutrophils undergo fragmentation and eventually become pyknotic, findings which support a pathogenetic role for neutrophil by-products (toxic oxygen radicals and proteolytic enzymes) in this form of lung injury. The fragmented neutrophils, nuclear dust, and fibrin also enter the alveolar spaces, and true fibrinoid necrosis of the interstitium may be seen.
        </p>
        <p>
         Causes of pulmonary capillaritis include the systemic vasculitides, antiglomerular basement membrane (anti-GBM; Goodpasture) disease, rheumatic diseases, certain drugs, and idiopathic pulmonary capillaritis  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ). Idiopathic pulmonary capillaritis, also known as pauci-immune pulmonary capillaritis, is characterized by the histopathologic findings of pulmonary capillaritis, but without clinical or serologic evidence of an associated systemic illness [
         <a href="#rid16">
          16
         </a>
         ]. It is classified within the family of idiopathic, small-vessel vasculitides, despite being antineutrophil cytoplasmic antibody negative [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Bland pulmonary hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bland pulmonary hemorrhage is characterized by hemorrhage into the alveolar spaces without inflammation or destruction of the alveolar structures  (
         <a class="graphic graphic_picture graphicRef52466" href="/z/d/graphic/52466.html" rel="external">
          picture 2
         </a>
         ). Causes include elevated left ventricular end diastolic pressure, bleeding disorders, and anticoagulant therapy  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid27">
          27-29
         </a>
         ]. Occasionally, anti-GBM disease or systemic lupus erythematosus can cause bland hemorrhage, although they are more commonly associated with pulmonary capillaritis.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Diffuse alveolar damage
         </span>
         <span class="headingEndMark">
          —
         </span>
         DAD, the underlying lesion of the acute respiratory distress syndrome (ARDS), can lead to alveolar hemorrhage  (
         <a class="graphic graphic_picture graphicRef53020" href="/z/d/graphic/53020.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid30">
          30-33
         </a>
         ]. DAD is characterized by edema of the alveolar septa and by formation of hyaline membranes that line the alveolar spaces. DAD has numerous causes, including cytotoxic and noncytotoxic drugs, infection, including coronavirus disease 2019 (COVID-19), rheumatic diseases, and other causes of ARDS  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid34">
          34,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">
          "Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with diffuse alveolar hemorrhage (DAH) present with a constellation of symptoms, signs, and laboratory results that may suggest a specific underlying diagnosis (eg, granulomatosis with polyangiitis, complications of drug therapy) or only permit the general diagnosis of the syndrome without favoring a specific etiology.
        </p>
        <p>
         Issues relating to the general presentation of patients with DAH will be reviewed first, followed by a discussion of the clinical findings that favor the diagnosis of a specific underlying cause.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The onset of DAH is most often abrupt or of short duration (less than seven days). Common initial symptoms are often nonspecific and may include cough, hemoptysis, fever, and dyspnea, although hemoptysis may be absent at presentation in one-third of patients. Some patients, however, present with acute severe respiratory distress requiring immediate ventilatory support with mechanical ventilation.
        </p>
        <p>
         The pulmonary examination is usually nonspecific; tachypnea, crackles, or bronchial breath sounds may be noted. The findings associated with individual causes of DAH are described below. (See
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Radiographic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         A chest radiograph is obtained in virtually all adults with recent onset of hemoptysis or dyspnea. The chest radiograph findings in DAH are nonspecific and most commonly show new patchy or diffuse opacities  (
         <a class="graphic graphic_diagnosticimage graphicRef61736 graphicRef73492" href="/z/d/graphic/61736.html" rel="external">
          image 1A-B
         </a>
         ).
        </p>
        <p>
         The finding of diffuse opacities on chest radiograph usually leads to thoracic computed tomography (CT) scanning to further characterize the abnormalities if the patient is sufficiently stable. In DAH, the characteristic findings on CT are ground glass or consolidative opacities that are usually diffuse and bilateral  (
         <a class="graphic graphic_diagnosticimage graphicRef79321" href="/z/d/graphic/79321.html" rel="external">
          image 2
         </a>
         ), but may occasionally be unilateral. These opacities tend to be more central than peripheral [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Recurrent episodes of DAH may lead to pulmonary fibrosis and reticular opacities, as seen in some patients with idiopathic pulmonary hemosiderosis [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4318.html" rel="external">
          "Idiopathic pulmonary hemosiderosis", section on 'Imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Laboratory abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory findings in DAH are often nonspecific. A low or decreasing hemoglobin and an elevated white blood cell count are common, but not essential to the diagnosis. Platelet counts may be increased or decreased relative to normal. The erythrocyte sedimentation rate is usually increased, particularly in those cases of DAH caused by systemic diseases. Coagulation abnormalities should be excluded by checking a platelet count, prothrombin time, international normalized ratio, and partial thromboplastin time. Iron deficiency may be present in patients with recurrent DAH.
        </p>
        <p>
         A number of diseases that result in the pulmonary-renal syndrome present with pulmonary hemorrhage in combination with focal segmental necrotizing glomerulonephritis. In this setting, an elevated plasma creatinine concentration, usually with an abnormal urinalysis (red blood cells, white blood cells, proteinuria, red and white blood cell casts), is typically seen. (See
         <a class="local">
          'Laboratory testing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1082580020">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse alveolar hemorrhage (DAH) is generally suspected in patients with hemoptysis, diffuse radiographic opacities, and severe gas transfer abnormalities. Sequential bronchoalveolar lavage (BAL) showing progressively more hemorrhagic effluent is the usual method for diagnosis of DAH. While an increased diffusing capacity for carbon monoxide (DLCO), when available, lends support for the diagnosis of DAH, most patients are not sufficiently stable to undergo pulmonary function testing. (See
         <a class="local">
          'Bronchoalveolar lavage'
         </a>
         below.)
        </p>
        <p>
         As noted, hemoptysis may be absent at presentation in up to 33 percent of patients with DAH from any cause. In the absence of hemoptysis, DAH should be suspected in patients with new respiratory symptoms and ground glass or consolidative opacities (either localized or diffuse) on imaging studies, especially when the patient has a decreasing hemoglobin level.
        </p>
        <p>
         The differential diagnosis of DAH includes acute respiratory distress syndrome (ARDS), multilobar pneumonia, aspiration pneumonitis, acute eosinophilic pneumonia, excessive anticoagulation, and pulmonary edema. Thus, the diagnostic approach is to seek affirmation of DAH via flexible bronchoscopy and to exclude infection, eosinophilia, or other alternative diagnoses.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Bronchoalveolar lavage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Flexible bronchoscopy with sequential BAL is the preferred method for diagnosis of DAH and should be performed promptly to expedite the evaluation. The fiberoptic bronchoscope is wedged into a subsegmental bronchus in an area where radiographic opacities are noted. Sequential BAL is performed by instilling and retrieving three aliquots of 50 to 60 mL sterile
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         from that subsegmental bronchus. Alveolar hemorrhage is confirmed when lavage aliquots are progressively more hemorrhagic, a finding characteristic of DAH from all causes. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage", section on 'Technique'
         </a>
         .)
        </p>
        <p>
         Hemosiderin-laden macrophages, which may be demonstrated by Prussian blue staining, are characteristically found in BAL fluid from patients with DAH, but are also reported in diffuse alveolar damage (DAD) and idiopathic pulmonary fibrosis [
         <a href="#rid37">
          37
         </a>
         ]. Prussian blue staining of BAL cells may be helpful in the diagnosis of DAH, especially in the absence of hemoptysis or a grossly hemorrhagic BAL. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage", section on 'Cytologic analysis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1082583043">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormal gas transfer is a characteristic finding in DAH. While the degree of hypoxemia varies, it is often of sufficient severity to require ventilatory support. Due to the severity of illness, most patients are unable to undergo pulmonary function testing. However, for patients who are stable enough to undergo pulmonary function testing, an
         <strong>
          increase
         </strong>
         in the DLCO above 100 percent of predicted or above a prior known value is a sensitive marker for DAH. The increase in DLCO results from the increased availability of hemoglobin within the alveolar compartment, which removes carbon monoxide from the exhaled air [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Monitoring the DLCO may be useful in detecting exacerbations of DAH in established cases, such as patients with idiopathic pulmonary hemosiderosis (IPH) or antiglomerular basement membrane (anti-GBM; Goodpasture) disease [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Occasionally, obstructive airways disease may be noted on spirometry in patients with recurrent DAH and pulmonary capillaritis secondary to microscopic polyangiitis (MPA) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Clues to a specific etiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clues to the underlying cause of DAH may be identified through a detailed history and physical examination, selected serologic and radiographic studies, BAL stains and culture, and biopsy of affected tissues. Identifying the underlying cause is often essential to successful treatment.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Useful diagnostic clues include a history of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exposure to possible offending drugs or other causative agents, such as abciximab,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , carbimazole, crack cocaine,
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          leflunomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">
          propylthiouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         , a tumor necrosis factor-alpha antagonist, or trimellitic anhydride [
         <a href="#rid40">
          40-42
         </a>
         ]. With crack cocaine inhalation, the cutting agent levamisole can cause DAD or capillaritis. A minority of cases of DAH are due to drug toxicity [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conditions associated with the development of ARDS including coronavirus disease 2019 (COVID-19) [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="local">
          'Diffuse alveolar damage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematopoietic cell transplantation, lung transplantation, and exposure to chemotherapeutic agents. (See
         <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">
          "Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4342.html" rel="external">
          "Pulmonary complications after autologous hematopoietic cell transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">
          "Evaluation and treatment of antibody-mediated lung transplant rejection", section on 'Acute antibody-mediated rejection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4327.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents", section on 'Gemcitabine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Agents targeting VEGF'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vaping, which has been associated with a number of acute lung injuries, including DAH [
         <a href="#rid44">
          44
         </a>
         ]; and cigarette smoking, which is a strong risk factor for DAH among patients with anti-GBM antibodies. (See
         <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic vasculitis or rheumatic disease; a history of thrombophlebitis or thrombocytopenia, which may suggest systemic lupus erythematosus (SLE) or antiphospholipid antibody syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermittent chest pain, palpitations, and peripheral edema might suggest mitral valve disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exposure to rodents or farm animals or travel to leptospirosis endemic areas (eg, Southeast Asia). (See
         <a class="medical medical_review" href="/z/d/html/5527.html" rel="external">
          "Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The physical examination in the patient with DAH is generally nonspecific; however, the presence of uveitis, nasal or oral ulcers, petechiae or palpable purpura  (
         <a class="graphic graphic_picture graphicRef78697" href="/z/d/graphic/78697.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef58626" href="/z/d/graphic/58626.html" rel="external">
          picture 5
         </a>
         ), foot drop, arthritis, or malar rash may suggest an underlying systemic disorder responsible for DAH (such as a vasculitis or rheumatic disease).
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the diagnosis of DAH is strongly suspected or has been diagnosed, additional laboratory tests are needed to identify the specific etiology  (
         <a class="graphic graphic_table graphicRef101060" href="/z/d/graphic/101060.html" rel="external">
          table 2
         </a>
         ). A key step is obtaining microbiologic studies to exclude infection. A blood urea nitrogen, creatinine, and urinalysis should be obtained in all patients to assess for a pulmonary-renal syndrome. An elevated plasma creatinine concentration and/or an abnormal urinalysis (red blood cells, white blood cells, proteinuria, red and white blood cell casts) are suggestive of a pulmonary-renal syndrome. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p>
         A brain natriuretic peptide (BNP) or N-terminal pro-BNP may be helpful if mitral stenosis or pulmonary edema is suspected. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure"
         </a>
         .)
        </p>
        <p>
         The finding of specific antibodies, positive microbiologic culture or specific staining, or positive drug screen may suggest or permit the diagnosis of a particular underlying disorder of DAH. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antineutrophil cytoplasmic antibodies (ANCA)
         </strong>
         – A positive ANCA can be associated with DAH due to granulomatosis with polyangiitis (GPA) or MPA [
         <a href="#rid7">
          7-10,45
         </a>
         ]. Cytoplasmic ANCA, as determined by immunofluorescence and antiproteinase 3 (anti-PR3) antibodies (by enzyme linked immunosorbent assay, anti-PR3 enzyme-linked immunoassay [ELISA]), is most consistent with GPA (90 percent of patients), while perinuclear ANCA (P-ANCA) with antimyeloperoxidase (anti-MPO) specificity (anti-MPO ELISA) favors the diagnosis of MPA or eosinophilic GPA (Churg-Strauss) syndrome; there is, however, some overlap  (
         <a class="graphic graphic_picture graphicRef66748 graphicRef78968" href="/z/d/graphic/66748.html" rel="external">
          picture 6A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiglomerular basement membrane antibodies
         </strong>
         – The possibility of anti-GBM antibody (Goodpasture) disease is evaluated by serologic testing for anti-GBM antibodies using a direct ELISA. A positive test is strongly suggestive of anti-GBM antibody disease, but a renal biopsy is frequently performed to confirm the diagnosis, unless contraindicated [
         <a href="#rid11">
          11,12
         </a>
         ]. The diagnosis of this condition is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serologic findings suggestive of systemic lupus erythematosus
         </strong>
         – Initial testing for SLE as an underlying cause of DAH usually includes complement levels (C3, C4, or CH50), antinuclear antibodies, and anti-double stranded DNA antibodies (anti-dsDNA) [
         <a href="#rid13">
          13
         </a>
         ]. The diagnosis of SLE is based on a set of clinical criteria that are discussed separately. If drug-induced SLE is suspected as a cause of DAH, additional testing should include antihistone antibodies  (
         <a class="graphic graphic_table graphicRef69467" href="/z/d/graphic/69467.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiphospholipid antibodies
         </strong>
         – The presence of anticardiolipin antibodies, anti-beta-2-glycoprotein I, and/or a lupus anticoagulant is consistent with the antiphospholipid syndrome. (See
         <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">
          "Clinical manifestations of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antitransglutaminase or antiendomysial immunoglobulin A (IgA) antibodies
         </strong>
         – The presence of antitransglutaminase or antiendomysial IgA antibodies may suggest the combination of celiac disease and pulmonary hemosiderosis, known as Lane-Hamilton syndrome. IPH most commonly occurs in children and young adults under age 30. (See
         <a class="medical medical_review" href="/z/d/html/4318.html" rel="external">
          "Idiopathic pulmonary hemosiderosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antistreptococcal antibodies or positive blood cultures
         </strong>
         – Antibodies directed against streptococcal antigens, including antistreptolysin O, anti-DNase B or hyaluronidase, or the documentation of positive blood cultures can suggest a diagnosis of poststreptococcal glomerulonephritis or bacterial endocarditis, respectively [
         <a href="#rid46">
          46,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3054.html" rel="external">
          "Kidney disease in the setting of infective endocarditis or an infected ventriculoatrial shunt"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug screening
         </strong>
         – Drug screening should be obtained in patients with suspected cocaine abuse. (See
         <a class="medical medical_review" href="/z/d/html/4343.html" rel="external">
          "Pulmonary complications of cocaine use"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          COVID-19
         </strong>
         – Severe acute respiratory syndrome coronavirus (SARS-CoV-2) nucleic acid amplification testing or antigen testing in patients presenting with ARDS and suspected pulmonary hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">
          "COVID-19: Diagnosis", section on 'Choosing an initial diagnostic test'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Radiographic and echocardiographic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain radiographic or echocardiographic findings may suggest a particular underlying disorder:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although the heart size is usually normal in DAH, cardiomegaly (from myocarditis or a pericardial effusion) is occasionally seen in DAH associated with the systemic vasculitides and rheumatic diseases. An abnormal left heart contour can be seen in mitral stenosis due to enlargement of the left atrium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary infarction can present as DAH, but the radiographic features differ. Pulmonary infarction is typically associated with segmental or subsegmental, wedge-shaped, pleural–based opacities, often with an ipsilateral pleural effusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kerley B lines on a chest radiograph point to the possible presence of mitral stenosis or pulmonary veno-occlusive disease [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Echocardiography can be used to evaluate for mitral stenosis. Left ventricular dysfunction, and elevated pulmonary artery pressures. (See
         <a class="medical medical_review" href="/z/d/html/8173.html" rel="external">
          "Rheumatic mitral stenosis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8269.html" rel="external">
          "Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Bronchoalveolar lavage
         </span>
         <span class="headingEndMark">
          —
         </span>
         While BAL is a key step in the diagnosis of DAH, it is of limited utility in identifying a specific etiology for DAH. In the setting of ARDS, culture, immunoassays (eg,
         <em>
          Pneumocystis
         </em>
         , viruses including SARS-CoV-2), and cytologic analysis of BAL fluid can be helpful in identifying an infectious agent responsible for the syndrome. (See
         <a class="medical medical_review" href="/z/d/html/4303.html" rel="external">
          "Basic principles and technique of bronchoalveolar lavage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biopsy of lung, kidney, or skin is occasionally needed when the diagnosis remains uncertain after the above evaluation. Generally, the biopsy site is chosen based on the least invasive method (skin, if a rash or purpura is present) or the greatest likelihood of securing a diagnosis (usually lung histopathology is more specific than kidney). Sometimes, a kidney biopsy is needed to assess the degree of kidney involvement or exclude concomitant diseases, even when there is a strong suspicion for a particular etiologic process such as anti-GBM disease or systemic vasculitis.
        </p>
        <p>
         In the presence of a rash, a skin biopsy may identify the diagnosis by demonstrating a leukocytoclastic vasculitis, eosinophilic GPA, or other vasculitis. Alternatively, the presence of IgA deposits in postcapillary venules is suggestive of IgA vasculitis (IgAV; Henoch-Schönlein purpura [HSP]). (See
         <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">
          "Overview of cutaneous small vessel vasculitis"
         </a>
         .)
        </p>
        <p>
         When a lung biopsy is needed to identify the cause of DAH, histopathologic clues to the etiology of DAH include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Linear IgG deposition along the pulmonary capillary basement membranes is virtually diagnostic of anti-GBM antibody (Goodpasture) disease, which sometimes is isolated to the lungs (5 to 10 percent of cases)  (
         <a class="graphic graphic_picture graphicRef63060" href="/z/d/graphic/63060.html" rel="external">
          picture 7
         </a>
         ) [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Marked granular immune complex deposition along the pulmonary capillary basement membranes is found in the rheumatic diseases, particularly SLE. If, however, the immune deposits are primarily IgA, then IgAV (HSP) or IgA nephropathy are the probable diagnoses [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lung biopsy in patients with DAH due to GPA, MPA, or isolated pulmonary capillaritis typically shows neutrophilic infiltration of the capillary wall and hemorrhage  (
         <a class="graphic graphic_picture graphicRef76904" href="/z/d/graphic/76904.html" rel="external">
          picture 1A
         </a>
         and
         <a class="graphic graphic_picture graphicRef56943" href="/z/d/graphic/56943.html" rel="external">
          picture 1B
         </a>
         ); larger vessels are often uninvolved. Small punctate neutrophilic aggregates and a small vessel leukocytoclastic vasculitis (ie, degenerating neutrophils with formation of nuclear dust in the vessel wall)  (
         <a class="graphic graphic_picture graphicRef101409" href="/z/d/graphic/101409.html" rel="external">
          picture 8
         </a>
         ) may be present. There are few, if any, deposits by immunofluorescence or electron microscopy (therefore called pauci-immune) in patients with GPA, MPA, or isolated pulmonary capillaritis [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Diffuse alveolar hemorrhage without systemic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the clinician has excluded drug and environmental exposures, mitral valve disease, bleeding disorders, and predisposing conditions that could lead to ARDS (and thereby DAH), four principal diagnostic possibilities remain:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-GBM antibody (Goodpasture) disease confined to the lung
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated pulmonary capillaritis with perinuclear or P-ANCA (usually directed against myeloperoxidase)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated pulmonary capillaritis without autoantibodies
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IPH
        </p>
        <p>
        </p>
        <p>
         Goodpasture disease can occasionally present or recur as DAH without glomerulonephritis [
         <a href="#rid12">
          12
         </a>
         ]. In this setting, circulating anti-GBM antibodies are often absent, and the only way to establish the diagnosis is by demonstrating linear immunofluorescence in lung tissue. The underlying histology may be either bland hemorrhage or pulmonary capillaritis.
        </p>
        <p>
         Isolated pulmonary capillaritis with or without P-ANCA positivity is a form of small vessel vasculitis limited to the lung [
         <a href="#rid8">
          8,16,23
         </a>
         ]. These entities do not fit into the usual vasculitic syndromes. Follow-up evaluation of ANCA-negative patients four years after initial presentation has found no evidence of further systemic involvement [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         IPH is a diagnosis of exclusion. The disease is primarily seen in younger patients, as only 20 percent of reported cases occur in adults [
         <a href="#rid50">
          50
         </a>
         ]. In the pediatric age group, this disorder is associated with celiac disease and elevated IgA levels in 50 percent of patients. These associations are lacking, however, in the majority of affected adults. The diagnosis of IPH is established by lung biopsy, which demonstrates bland pulmonary hemorrhage without immune complexes. It is likely, however, that cases of isolated pulmonary capillaritis have been diagnosed as IPH, since pathologists are generally unfamiliar with the capillaritis lesion described above. (See
         <a class="medical medical_review" href="/z/d/html/4318.html" rel="external">
          "Idiopathic pulmonary hemosiderosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of diffuse alveolar hemorrhage (DAH) has not been rigorously studied in randomized trials except in the context of severe presentations of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and mixed cryoglobulinemia, so treatment decisions are based upon extrapolation from these studies (when capillaritis is suspected), observations from case series, and our clinical experience.
        </p>
        <p>
         When an underlying cause is identified, specific treatment of that disease or process is appropriate when available. Thus, cessation of implicated drugs and exposures, treatment of infection, and reversal of excess anticoagulation are key. Inflammatory causes of DAH (eg, rheumatic diseases, differentiation [retinoic acid] syndrome, and some drug-induced) are typically treated with systemic glucocorticoids, with additional immunosuppressive therapy as described below.
        </p>
        <p>
         Given that the differential diagnosis for DAH includes acute respiratory distress syndrome due to infection, careful evaluation to exclude infection must be performed prior to initiation of systemic glucocorticoids or immunosuppressive therapy. As prompt therapy for DAH is essential, empiric antimicrobial therapy is often initiated while waiting for results of microbial studies.
        </p>
        <p class="headingAnchor" id="H1414918277">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with DAH typically have hypoxemia requiring supplemental oxygen; often the hypoxemia is severe enough to require noninvasive or invasive mechanical ventilation. The implementation of noninvasive or invasive mechanical ventilation for acute respiratory failure is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">
          "Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">
          "Acute respiratory distress syndrome: Ventilator management strategies for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"
         </a>
         .)
        </p>
        <p>
         Extracorporeal membrane oxygenation (ECMO) has been used in a few patients to support patients with refractory hypoxemic respiratory failure due to DAH [
         <a href="#rid51">
          51
         </a>
         ]. However, the use of ECMO in this setting is controversial due to the necessity for anticoagulation and the attendant risk of worsening alveolar hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">
          "Extracorporeal life support in adults in the intensive care unit: Overview"
         </a>
         .)
        </p>
        <p>
         All known or suspected coagulation abnormalities should be reversed, as described below. In addition, patients with severe hemoptysis may require general supportive therapy that is based on the degree of bleeding. (See
         <a class="local">
          'Excess anticoagulation or bleeding disorder'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1414918214">
         <span class="h2">
          Diffuse alveolar hemorrhage with capillaritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         DAH with capillaritis is a life-threatening condition and requires prompt treatment. The majority of diseases causing capillaritis are treated with a combination of systemic glucocorticoids and immunosuppressive therapy such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         with or without plasmapheresis. Often, high-dose glucocorticoids are initiated while waiting for the results of testing to confirm a specific cause of capillaritis, which will then guide selection of an additional immunosuppressive agent.
        </p>
        <p class="headingAnchor" id="H10847695">
         <span class="h3">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with DAH due to capillaritis (eg, systemic vasculitis, antiglomerular basement membrane [anti-GBM] syndrome, or rheumatic disease), we initiate systemic glucocorticoid therapy promptly, as glucocorticoids are part of accepted regimens for all of these diseases. By extrapolation, we also use systemic glucocorticoids for patients with isolated, pauci-immune pulmonary capillaritis [
         <a href="#rid16">
          16,23
         </a>
         ]. Most experts, including us, administer intravenous pulse
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (500 to 1000 mg in divided daily doses) for up to five days followed by transition to an oral preparation with gradual tapering to a maintenance dose.
        </p>
        <p class="headingAnchor" id="H10847702">
         <span class="h3">
          Additional immunosuppressive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision about which specific immunosuppressive agent (eg,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , plasma exchange) to initiate for DAH with capillaritis is dependent upon the severity of the illness, the anticipated responsiveness to glucocorticoids, and the specific underlying disease.
        </p>
        <p>
         Some disease-specific suggestions are outlined here:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic vasculitis
         </strong>
         – For patients with DAH due to granulomatosis with polyangiitis or microscopic polyangiitis, we recommend prompt initiation of an induction regimen consisting of either
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in combination with pulse glucocorticoid therapy, rather than other agents or glucocorticoids alone. This is based on data from the landmark multicenter, randomized RAVE trial, which demonstrated similar efficacy of rituximab and cyclophosphamide for inducing remission in severe ANCA-associated vasculitis [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An important caveat to the RAVE study is that the true efficacy of either
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         has not been rigorously assessed in patients with respiratory failure due to DAH. Approximately a quarter of the patients in the trial presented with alveolar hemorrhage, but did not require intubation at baseline. A separate single-center retrospective analysis that included 68 ANCA-positive patients with DAH, of which 31 required intubation, found that rituximab was associated with a higher rate of achieving complete remission by six months compared with cyclophosphamide (odds ratio 6.45, 95% CI 1.78-29), including the patients with respiratory failure [
         <a href="#rid53">
          53
         </a>
         ]. The advantages and disadvantages of selecting cyclophosphamide versus rituximab in this setting are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Initial treatment approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients treated with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , it is our practice to give one intravenous dose of cyclophosphamide (0.75 g/m
         <sup>
          2
         </sup>
         if renal function is relatively normal). We subsequently pay close attention to the nadir of the peripheral white blood cell count and initiate oral therapy in approximately two weeks if neutropenia does not occur. (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Initial treatment approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For treatment with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , we use the dose that was used in the RAVE trial, specifically 375 mg/m
         <sup>
          2
         </sup>
         per week for four weeks. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Rituximab-based regimen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of plasma exchange for life-threatening or ventilator-dependent DAH secondary to vasculitis remains controversial, as retrospective studies have demonstrated mixed results and randomized trials have not been performed [
         <a href="#rid53">
          53-55
         </a>
         ]. We individualize the use of plasma exchange in patients with vasculitis-associated, life-threatening DAH, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Role of plasma exchange'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiglomerular basement membrane antibody (Goodpasture) disease
         </strong>
         – For patients with DAH due to anti-GBM antibody (Goodpasture) disease, concurrent plasma exchange, high-dose glucocorticoids, and an immunosuppressive agent (preferably
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) are recommended. Several retrospective studies and a small, randomized trial have demonstrated improved outcomes in patients with anti-GBM disease treated with plasma exchange, and its use has thus become standard of care. The treatment of anti-GBM disease is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3085.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Treatment and prognosis", section on 'Initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe mixed cryoglobulinemia
         </strong>
         – In the setting of mixed cryoglobulinemia complicated by DAH, it is critical to identify and treat the underlying inciting condition whenever possible. Patients with HIV or hepatitis B should receive antiviral therapy prior to or concurrent with immunosuppressive therapy; those with hepatitis C can receive immunosuppression prior to receiving antiviral treatment. Immunosuppressive therapy typically consists of pulse glucocorticoids followed by a taper plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or, if rituximab is unavailable,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . Although convincing evidence for plasma exchange in mixed cryoglobulinemia is lacking, some providers recommend its use for severe cases that involve the hyperviscosity syndrome or pulmonary hemorrhage [
         <a href="#rid56">
          56
         </a>
         ]. Importantly, care must be taken to warm the exchange fluid to prevent precipitation of circulating cryoglobulins. The details of immunosuppressive and antiviral therapy in mixed cryoglobulinemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Treatment and prognosis", section on 'Summary and recommendations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), or catastrophic APS
         </strong>
         – DAH in the setting of SLE or APS is typically treated with intravenous pulses of
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (500 to 1000 mg for three to five days) in combination with an additional immunosuppressive agent. Although
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         is often used, alternative regimens with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         have been reported, and no randomized trials comparing agents exist [
         <a href="#rid57">
          57-66
         </a>
         ]. Catastrophic APS is a life-threatening form of APS with rapid onset multiorgan involvement that can include DAH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The management of DAH due to SLE or CAPS is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Treatment and prognosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106168.html" rel="external">
          "Catastrophic antiphospholipid syndrome (CAPS)", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Concurrent pulmonary infection is common in patients with DAH secondary to SLE, with an incidence ranging from 32 to 45 percent in two small series [
         <a href="#rid58">
          58,67
         </a>
         ]. Therefore, empiric coverage with antibiotics prior to the initiation of immunosuppression is advisable, pending results of studies to exclude infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isolated pauci-immune pulmonary capillaritis
         </strong>
         – Initial treatment of isolated pauci-immune pulmonary capillaritis associated with DAH generally includes a combination of systemic glucocorticoids and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , similar to the induction regimens for systemic vasculitis described above. Data for pauci-immune DAH are limited to isolated cases, and there are no studies to suggest the superiority of one immunosuppressant agent over another [
         <a href="#rid3">
          3,16,23
         </a>
         ]. For patients not requiring mechanical ventilation, systemic glucocorticoid dosing with the equivalent of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg per day is reasonable; for patients with respiratory failure, high-dose
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         is usually substituted.
        </p>
        <p>
        </p>
        <p>
         The possible role of intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         in patients with DAH due to vasculitis or other rheumatic disease is unknown.
        </p>
        <p class="headingAnchor" id="H1414918620">
         <span class="h2">
          Drug-induced diffuse alveolar hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drug-induced DAH can arise from a capillaritis resembling that seen in the systemic vasculitides and connective tissue diseases, which may represent an autoimmune or hypersensitivity reaction to the drug [
         <a href="#rid68">
          68
         </a>
         ]. When drug-induced DAH is suspected, the culprit agent should be stopped immediately, and treatment decisions involving the use of immunosuppression for severe or refractory cases are extrapolated from the treatment of DAH secondary to underlying autoimmune conditions.
        </p>
        <p>
         For most patients with actual or impending respiratory failure, we suggest initiation of systemic glucocorticoids. This choice is based upon the potentially life-threatening nature of DAH, the response to glucocorticoids described in case reports, and evidence of an inflammatory component in the few patients who underwent lung biopsy [
         <a href="#rid2">
          2,69,70
         </a>
         ]. However, the use of systemic glucocorticoids in this setting has not been formally evaluated, and in milder cases or where systemic glucocorticoids are contraindicated, a more conservative approach of simply stopping the culprit drug with close observation may be acceptable.
        </p>
        <p class="headingAnchor" id="H1414918365">
         <span class="h2">
          Excess anticoagulation or bleeding disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         When DAH is caused by drugs or processes that result in a bleeding disorder, the mainstays of therapy are reversal of excess anticoagulation and treatment of the bleeding diathesis.
        </p>
        <p>
         As DAH is life-threatening, it is an indication for discontinuation of anticoagulant agents and, depending on the specific agent, administration of
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         ,
         <a class="drug drug_general" data-topicid="9450" href="/z/d/drug information/9450.html" rel="external">
          4-factor prothrombin complex concentrate
         </a>
         , antifibrinolytic agents, and/or platelet transfusions  (
         <a class="graphic graphic_table graphicRef96230" href="/z/d/graphic/96230.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">
          "Management of bleeding in patients receiving direct oral anticoagulants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p>
         A number of processes can cause thrombocytopenia resulting in DAH, including immune thrombocytopenia, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome. The management of these diseases is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6677.html" rel="external">
          "Initial treatment of immune thrombocytopenia (ITP) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">
          "Immune TTP: Initial treatment"
         </a>
         .)
        </p>
        <p>
         The use of recombinant human coagulation factor VIIa in patients with DAH or other cause of pulmonary hemorrhage is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">
          "Recombinant factor VIIa: Administration and adverse effects", section on 'CNS bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H990863835">
         <span class="h2">
          Idiopathic pulmonary hemosiderosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic pulmonary hemosiderosis (IPH) is considered a form of bland hemorrhage (see
         <a class="local">
          'Bland pulmonary hemorrhage'
         </a>
         above), but patients with this condition benefit from long-term glucocorticoid therapy. For patients with an acute episode of DAH due to IPH, we suggest systemic glucocorticoid therapy, as case reports and case series suggest that systemic glucocorticoids reduce morbidity and mortality during acute episodes of alveolar bleeding. In the setting of respiratory failure, we recommend intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ; we typically start with a pulse dose of 500 to 1000 mg per day for up to five days. The use of glucocorticoids in IPH is described separately. (See
         <a class="medical medical_review" href="/z/d/html/4318.html" rel="external">
          "Idiopathic pulmonary hemosiderosis", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         The role of additional immunosuppressive therapy is less clear. Case reports have described success with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">
          hydroxychloroquine
         </a>
         , but most of these cases were in patients requiring chronic suppressive therapy, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/4318.html" rel="external">
          "Idiopathic pulmonary hemosiderosis", section on 'Immunosuppressive drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1414918420">
         <span class="h2">
          Diffuse alveolar damage due to infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with DAH caused by diffuse alveolar damage due to infection (ie, adult respiratory distress syndrome) require prompt initiation of broad spectrum antimicrobial therapy, possibly including antiviral therapy depending on the presentation, while awaiting results of microbial studies. (See
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Intensive care unit'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1414918433">
         <span class="h2">
          Elevated pulmonary capillary pressures
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of pulmonary vein stenosis, pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, and mitral stenosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">
          "Rheumatic mitral stenosis: Overview of management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8269.html" rel="external">
          "Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults", section on 'Clinical manifestations of pulmonary hypertension'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Experimental therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         A retrospective review of DAH in allogeneic hematopoietic cell transplant recipients found an improved survival in eight patients treated with
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         infusion in addition to
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , compared with methylprednisolone alone [
         <a href="#rid71">
          71
         </a>
         ]. However, a subsequent study did not find a benefit to aminocaproic acid in this setting [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repeated episodes of diffuse alveolar hemorrhage (DAH) can result in irreversible interstitial fibrosis, particularly in patients with underlying idiopathic pulmonary hemosiderosis (IPH), granulomatosis with polyangiitis, and mitral stenosis. In addition, a post-DAH syndrome that consists of severe progressive obstructive lung disease and emphysema has been described in patients with recurrent DAH due to microscopic polyangiitis [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The short- and long-term survival rates vary with the underlying cause of DAH. Patients with systemic lupus erythematosus, vasculitis, antiglomerular basement membrane antibody disease, and IPH have a very high early mortality with rates ranging from 25 to 50 percent [
         <a href="#rid1">
          1
         </a>
         ]. Nevertheless, these immune causes of DAH can be successfully treated with subsequent long-term remission, whereas many patients with nonimmune etiologies have severe comorbidities that portend a poor prognosis. For example, in one retrospective study evaluating 88 patients, those with nonimmune DAH were more likely to die than patients with immune-mediated DAH [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10847330">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – The syndrome of diffuse alveolar hemorrhage (DAH) is caused by injury or inflammation of the arterioles, venules, or alveolar septal (alveolar wall or interstitial) capillaries. DAH is associated with a wide variety of disease processes  (
         <a class="graphic graphic_table graphicRef52374" href="/z/d/graphic/52374.html" rel="external">
          table 1
         </a>
         ) that can be divided into three categories, pulmonary capillaritis  (
         <a class="graphic graphic_picture graphicRef76904 graphicRef56943" href="/z/d/graphic/76904.html" rel="external">
          picture 1A-B
         </a>
         ), bland alveolar hemorrhage  (
         <a class="graphic graphic_picture graphicRef52466" href="/z/d/graphic/52466.html" rel="external">
          picture 2
         </a>
         ), and diffuse alveolar damage  (
         <a class="graphic graphic_picture graphicRef53020" href="/z/d/graphic/53020.html" rel="external">
          picture 3
         </a>
         ). (See
         <a class="local">
          'Etiology and histology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Cough, hemoptysis, fever, and dyspnea are common initial symptoms, although hemoptysis may be
         <strong>
          absent
         </strong>
         in up to 33 percent of patients with DAH from any cause. New radiographic opacities (either localized or diffuse), a falling hemoglobin level, and the finding of increasingly hemorrhagic fluid on sequential bronchoalveolar lavage (BAL) favor the diagnosis. (See
         <a class="local">
          'Symptoms and signs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         –
         <strong>
         </strong>
         DAH is generally suspected in patients with hemoptysis, diffuse radiographic opacities, and severe gas transfer abnormalities, although hemoptysis can be absent in up to a third of patients. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory testing
         </strong>
         – Laboratory testing focuses on bleeding disorders, concomitant kidney disease, and clues to an underlying cause  (
         <a class="graphic graphic_table graphicRef101060" href="/z/d/graphic/101060.html" rel="external">
          table 2
         </a>
         ). A key step is obtaining microbiologic studies to identify or exclude infection (eg, bacterial pneumonia, coronavirus disease 2019 [COVID-19]). (See
         <a class="local">
          'Laboratory testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging
         </strong>
         – Thoracic computed tomography scanning typically shows ground glass or consolidative opacities that are diffuse and bilateral  (
         <a class="graphic graphic_diagnosticimage graphicRef79321" href="/z/d/graphic/79321.html" rel="external">
          image 2
         </a>
         ) but spare the periphery; opacities may occasionally be unilateral. (See
         <a class="local">
          'Radiographic findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bronchoalveolar lavage
         </strong>
         – Sequential BAL in an area where radiographic opacities are noted is a key step in the diagnosis of DAH, although it rarely identifies a specific etiology. Progressively more hemorrhagic BAL is characteristic of DAH from all causes. (See
         <a class="local">
          'Bronchoalveolar lavage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Identifying an underlying cause
         </strong>
         – Once the diagnosis of DAH is made, the underlying cause is sought through careful review of the history (including medication use, toxic or infectious exposures, extrapulmonary symptoms), physical examination (especially skin), and laboratory tests  (
         <a class="graphic graphic_table graphicRef101060" href="/z/d/graphic/101060.html" rel="external">
          table 2
         </a>
         ). A skin biopsy may be helpful in patients with a rash suggestive of vasculitis or immunoglobulin A vasculitis (Henoch-Schönlein purpura). When the underlying cause remains unclear after a careful evaluation, a lung or kidney biopsy may be necessary to determine the underlying cause. (See
         <a class="local">
          'Biopsy'
         </a>
         above and
         <a class="local">
          'Clues to a specific etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Prompt initiation of therapy is required due to the life-threatening nature of DAH. Depending on whether the underlying cause of DAH is clear or remains under investigation, initial therapy will be empiric (pending identification of the cause) or cause-specific.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Supportive care
         </strong>
         – For all patients, supportive care typically includes supplemental oxygen; noninvasive or invasive mechanical ventilation may be needed depending on the severity of hypoxemia. Patients with severe hemoptysis/DAH may require additional interventions. (See
         <a class="local">
          'Supportive care'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">
          "Evaluation and management of life-threatening hemoptysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial empiric therapy
         </strong>
         – For patients in whom the underlying cause of DAH is unclear, we recommend broad spectrum antibiotics and systemic glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). DAH is a life-threatening condition, and prompt initiation of therapy can be life-saving.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Acute respiratory distress syndrome (ARDS) due to infection (eg, bacteria, viral including COVID-19) is a common cause of DAH, so empiric broad spectrum antimicrobial therapy, possibly including antiviral therapy, should initiated while waiting for results of microbial studies. (See
         <a class="local">
          'Treatment'
         </a>
         above and
         <a class="local">
          'Diffuse alveolar damage due to infection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Intensive care unit'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Systemic glucocorticoids are part of the initial regimen for many of the causes of DAH (eg, systemic vasculitis, rheumatic disease, antiglomerular basement membrane (anti-GPM; Goodpasture) disease, idiopathic pulmonary hemosiderosis [IPH]). A reasonable initial dose is pulse
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         500 to 1000 mg/day intravenously in divided doses, for up to five days, followed by transition to oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and then gradual tapering. For stable patients with mild IPH, oral therapy is an alternative. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Drugs that are potential causes of DAH should be withheld. Excess anticoagulation should be reversed. (See
         <a class="local">
          'Drug-induced diffuse alveolar hemorrhage'
         </a>
         above and
         <a class="local">
          'Elevated pulmonary capillary pressures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cause-specific therapy
         </strong>
         – Once the cause of DAH is identified, therapy is focused accordingly:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with ARDS due to infection, initial empiric antimicrobial therapy (eg, antibacterial, antiviral) should be tailored to cover implicated organisms. (See
         <a class="local">
          'Diffuse alveolar damage due to infection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Intensive care unit'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For drug-induced DAH, in addition to cessation of the culprit drug, we suggest systemic glucocorticoid therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), due to the potential severity of the disease and the histopathologic observation of inflammation in some patients. Exceptions might include patients who are stable, do not require mechanical ventilation, or have a contraindication to glucocorticoids. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Specific treatment of DAH due to systemic vasculitis, rheumatic disease, and anti-GPM disease virtually always includes pulse
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (500 to 1000 mg/day intravenously in divided doses) for up to five days, followed by transition to oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg per day and then gradual tapering. For IPH, systemic glucocorticoids are dosed according to the severity of DAH. Treatment of many of these diseases requires additional immunosuppressive therapy (eg,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , plasma exchange), as described separately. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Initial treatment approach'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Treatment and prognosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3085.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4318.html" rel="external">
          "Idiopathic pulmonary hemosiderosis", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For DAH caused by excess anticoagulation or a bleeding disorder, the mainstays of treatment are reversal of medication-induced anticoagulation and treatment of any bleeding diathesis. Additional therapy, depending on the specific cause of the bleeding disorder, may include administration of
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         ,
         <a class="drug drug_general" data-topicid="9450" href="/z/d/drug information/9450.html" rel="external">
          4-factor prothrombin complex concentrate
         </a>
         , antifibrinolytic agents, platelet transfusions, or plasma exchange  (
         <a class="graphic graphic_table graphicRef96230" href="/z/d/graphic/96230.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Excess anticoagulation or bleeding disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3051105291">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Marvin I Schwarz, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Franks TJ, Koss MN. Pulmonary capillaritis. Curr Opin Pulm Med 2000; 6:430.
          </a>
         </li>
         <li class="breakAll">
          Lara AR, Frankel SK, Schwarz MI. Diffuse alveolar hemorrhage. In: Interstitial Lung Disease, 5th ed, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House, Shelton, CT, USA 2011. p.805.
         </li>
         <li class="breakAll">
          Collard HR, King TE Jr, Schwarz MI. Diffuse alveolar hemorrhage and rare infiltrative disorders of the lung. In: Murray &amp; Nadel's Textbook of Respiratory Medicine, 6th, Broaddus VC, Mason RJ, Ernst JD, Lazarus SC, King TE Jr, Murray JF, Nadel JA, Slutsky AS, Gotway MB (Eds), Elsevier, New York 2016. p.1207.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mark EJ, Ramirez JF. Pulmonary capillaritis and hemorrhage in patients with systemic vasculitis. Arch Pathol Lab Med 1985; 109:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leatherman JW. The lung in systemic vasculitis. Semin Respir Infect 1988; 3:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Colby TV, Lombard C, Carpenter HA. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990; 14:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenclud C, De Vuyst P, Dupont E, et al. Wegener's granulomatosis presenting as acute respiratory failure with anti-neutrophil-cytoplasm antibodies. Chest 1989; 96:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosch X, López-Soto A, Mirapeix E, et al. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage. Arch Pathol Lab Med 1994; 118:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudin PB, Askin FB, Falk RJ, Jennette JC. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol 1995; 104:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly PT, Haponik EF. Goodpasture syndrome: molecular and clinical advances. Medicine (Baltimore) 1994; 73:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobler A, Schürch E, Altermatt HJ, Im Hof V. Anti-basement membrane antibody disease with severe pulmonary haemorrhage and normal renal function. Thorax 1991; 46:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers JL, Katzenstein AA. Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol 1986; 85:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz MI, Sutarik JM, Nick JA, et al. Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis. Am J Respir Crit Care Med 1995; 151:2037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torralbo A, Herrero JA, Portolés J, Barrientos A. Alveolar hemorrhage associated with antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Chest 1994; 105:1590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennings CA, King TE Jr, Tuder R, et al. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med 1997; 155:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertner E, Lie JT. Pulmonary capillaritis, alveolar hemorrhage, and recurrent microvascular thrombosis in primary antiphospholipid syndrome. J Rheumatol 1993; 20:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robboy SJ, Minna JD, Colman RW, et al. Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases. Chest 1973; 63:718.
          </a>
         </li>
         <li class="breakAll">
          Haselton PS. Adult respiratory distress syndrome. In: Spencers Pathology of the Lung, Haselton PS (Ed), McGraw Hill, New York 1996. p.375.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz MI, Zamora MR, Hodges TN, et al. Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease. Chest 1998; 113:1609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandre AT, Vale A, Gomes T. Diffuse alveolar hemorrhage: how relevant is etiology? Sarcoidosis Vasc Diffuse Lung Dis 2019; 36:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colby TV, Fukuoka J, Ewaskow SP, et al. Pathologic approach to pulmonary hemorrhage. Ann Diagn Pathol 2001; 5:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz MI, Brown KK. Small vessel vasculitis of the lung. Thorax 2000; 55:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazor R, Bigay-Gamé L, Cottin V, et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore) 2007; 86:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhillon SS, Singh D, Doe N, et al. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 1999; 116:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown KK. Pulmonary vasculitis. Proc Am Thorac Soc 2006; 3:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bansal S, Khan R, Cicenia J, et al . Alveolar hemorrhage associated with administration of glycoprotein IIA/IIIB inhibitor eptifibatide. Crit Care Med 2006; 34:A165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bast A, Drent M. The role of vitamin K in the etiology of diffuse alveolar hemorrhage. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erdogan D, Kocaman O, Oflaz H, Goren T. Alveolar hemorrhage associated with warfarin therapy: a case report and literature review. Int J Cardiovasc Imaging 2004; 20:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EA, Lee KS, Primack SL, et al. Viral pneumonias in adults: radiologic and pathologic findings. Radiographics 2002; 22 Spec No:S137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandrescu DT, Dutcher JP, O'Boyle K, et al. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45:2321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anantham D, Chan KP, Chuah KL, et al. Pulmonary capillaritis in IgA nephropathy. South Med J 2007; 100:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luks AM, Lakshminarayanan S, Hirschmann JV. Leptospirosis presenting as diffuse alveolar hemorrhage: case report and literature review. Chest 2003; 123:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spira D, Wirths S, Skowronski F, et al. Diffuse alveolar hemorrhage in patients with hematological malignancies: HRCT patterns of pulmonary involvement and disease course. Clin Imaging 2013; 37:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raanani P, Segal E, Levi I, et al. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA--a manifestation of the basic disease or the treatment. Leuk Lymphoma 2000; 37:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichtenberger JP 3rd, Digumarthy SR, Abbott GF, et al. Diffuse pulmonary hemorrhage: clues to the diagnosis. Curr Probl Diagn Radiol 2014; 43:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Lassence A, Fleury-Feith J, Escudier E, et al. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 1995; 151:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greening AP, Hughes JM. Serial estimations of carbon monoxide diffusing capacity in intrapulmonary haemorrhage. Clin Sci (Lond) 1981; 60:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz MI, Mortenson RL, Colby TV, et al. Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation. Am Rev Respir Dis 1993; 148:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004; 79:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeiss CR, Wolkonsky P, Chacon R, et al. Syndromes in workers exposed to trimellitic anhydride. A longitudinal clinical and immunologic study. Ann Intern Med 1983; 98:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006; 73:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 2020; 77:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmonds PJ, Copeland C, Conger A, Richmond BW. Vaping-induced diffuse alveolar hemorrhage. Respir Med Case Rep 2020; 29:100996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 2000; 79:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thangaraj Y, Ather I, Chataut H, et al. Diffuse alveolar hemorrhage as a presentation of acute poststreptococcal glomerulonephritis. Am J Med 2014; 127:e15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu HC, Wen YK, Chen ML, Fan CS. Pulmonary-renal syndrome in a patient with bacterial endocarditis. J Formos Med Assoc 2005; 104:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest 2010; 137:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeager H Jr, Powell D, Weinberg RM, et al. Idiopathic pulmonary hemosiderosis: ultrastructural studies and responses to azathioprine. Arch Intern Med 1976; 136:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrams D, Agerstrand CL, Biscotti M, et al. Extracorporeal membrane oxygenation in the management of diffuse alveolar hemorrhage. ASAIO J 2015; 61:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, et al. Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis Rheumatol 2016; 68:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Luna G, Chauveau D, Aniort J, et al. Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. J Autoimmun 2015; 65:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gómez-Puerta JA, Hernández-Rodríguez J, López-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest 2009; 136:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci 2010; 42:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun Y, Zhou C, Zhao J, et al. Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China. Lupus 2020; 29:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Martínez MU, Abud-Mendoza C. Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. Lupus 2011; 20:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pottier V, Pierrot M, Subra JF, et al. Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus 2011; 20:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Echavarri C, Pernas B, Ugarte A, Ruiz-Irastorza G. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. Lupus 2014; 23:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tse JR, Schwab KE, McMahon M, Simon W. Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus. Lupus 2015; 24:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Na JO, Chang SH, Seo KH, et al. Successful early rituximab treatment in a case of systemic lupus erythematosus with potentially fatal diffuse alveolar hemorrhage. Respiration 2015; 89:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartin-Ceba R, Peikert T, Ashrani A, et al. Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. Arthritis Care Res (Hoboken) 2014; 66:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yachoui R, Sehgal R, Amlani B, Goldberg JW. Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. Semin Arthritis Rheum 2015; 44:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ednalino C, Yip J, Carsons SE. Systematic Review of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Focus on Outcome and Therapy. J Clin Rheumatol 2015; 21:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Adhoubi NK, Bystrom J. Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies. Lupus 2020; 29:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997; 76:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med 2004; 25:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magee F, Wright JL, Chan N, et al. Two unusual pathological reactions to nitrofurantoin: case reports. Histopathology 1986; 10:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iskandar SB, Abi-Saleh B, Keith RL, et al. Amiodarone-induced alveolar hemorrhage. South Med J 2006; 99:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanko SO, Broadwater G, Folz RJ, Chao NJ. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant 2006; 12:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rathi NK, Tanner AR, Dinh A, et al. Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage. Bone Marrow Transplant 2015; 50:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhushan A, Choi D, Maresh G, Deodhar A. Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience. Rheumatol Int 2022; 42:485.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4341 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10958235" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pulmonary capillaritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10958235" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pulmonary capillaritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10958235" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Pulmonary capillaritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3838654" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pulmonary capillaritis and hemorrhage in patients with systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2903521" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The lung in systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2252102" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2666045" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Wegener's granulomatosis presenting as acute respiratory failure with anti-neutrophil-cytoplasm antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7910729" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7611186" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4048389" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Microscopic polyarteritis: presentation, pathology and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8041241" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Goodpasture syndrome: molecular and clinical advances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1871699" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Anti-basement membrane antibody disease with severe pulmonary haemorrhage and normal renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3706197" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Microangiitis in lupus-induced pulmonary hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7767555" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8181365" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Alveolar hemorrhage associated with antineutrophil cytoplasmic antibodies in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9116994" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8371225" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pulmonary capillaritis, alveolar hemorrhage, and recurrent microvascular thrombosis in primary antiphospholipid syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4634077" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4634077" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9631801" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32476936" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Diffuse alveolar hemorrhage: how relevant is etiology?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11598860" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pathologic approach to pulmonary hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10817800" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Small vessel vasculitis of the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17505257" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10559122" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16493151" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pulmonary vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Alveolar hemorrhage associated with administration of glycoprotein IIA/IIIB inhibitor eptifibatide
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32476960" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The role of vitamin K in the etiology of diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15068147" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Alveolar hemorrhage associated with warfarin therapy: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12376607" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Viral pneumonias in adults: radiologic and pathologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15512824" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17591315" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pulmonary capillaritis in IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12576395" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Leptospirosis presenting as diffuse alveolar hemorrhage: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23313188" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Diffuse alveolar hemorrhage in patients with hematological malignancies: HRCT patterns of pulmonary involvement and disease course.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11042521" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA--a manifestation of the basic disease or the treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24791616" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Diffuse pulmonary hemorrhage: clues to the diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7812547" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7249536" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Serial estimations of carbon monoxide diffusing capacity in intrapulmonary haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8102044" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15065619" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Sirolimus-associated diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6848046" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Syndromes in workers exposed to trimellitic anhydride. A longitudinal clinical and immunologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17127088" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32364264" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31956478" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Vaping-induced diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10941351" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24927907" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Diffuse alveolar hemorrhage as a presentation of acute poststreptococcal glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16193181" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Pulmonary-renal syndrome in a patient with bacterial endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11069841" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pulmonary veno-occlusive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20442117" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/971014" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Idiopathic pulmonary hemosiderosis: ultrastructural studies and responses to azathioprine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25485559" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Extracorporeal membrane oxygenation in the management of diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20647199" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26713723" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26330347" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19809051" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20382569" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Plasma exchange for treating cryoglobulinemia: a descriptive analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32321345" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21558137" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21335399" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24531426" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25527066" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25531296" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Successful early rituximab treatment in a case of systemic lupus erythematosus with potentially fatal diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23983016" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25481816" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26308350" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Systematic Review of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Focus on Outcome and Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32036761" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9193454" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15062605" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3744305" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Two unusual pathological reactions to nitrofurantoin: case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16634249" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Amiodarone-induced alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16920561" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25531284" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33782747" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
